Cassidy Blaiss, PharmD
Since the start of the decade, antibody–drug conjugates (ADCs) have been yielding improved survival rates in patients with gynecologic malignancies (GMs), including a doubling of progression-free survival (PFS). However, as ADCs trend toward “being an important mainstay in gynecologic oncology,” clinicians must help patients cope with associated toxicities—actions that the profession is well equipped to handle, Cassidy Blaiss, PharmD, BCOP,